Unraveling the Mystery: A Maltese Scientist’s Quest to Crack a Rare Childhood ALS Case

Imagine a child, barely old enough to hold a pencil, struggling to write their name. Their small hand trembles, the once fluid letters now a laborious, jerky scrawl. This isn’t a sign of a developmental delay, but a harbinger of a devastating disease – a rare childhood form of Amyotrophic Lateral Sclerosis (ALS), a condition more commonly associated with late-onset cases. This is the reality that Dr. Maria Azzopardi, a Maltese neuroscientist, is grappling with in her lab at the University of Malta’s Department of Physiology and Biochemistry.

ALS in miniature: A rare childhood form

ALS, often referred to as Lou Gehrig’s disease, is a progressive neurodegenerative disease that affects the nerve cells in the brain and the spinal cord. It’s a condition that’s typically diagnosed in adults, with only about 5% of cases occurring in children. Yet, when it does strike the young, it’s often a more aggressive and rapidly progressing form of the disease. This is the heartbreaking reality that Dr. Azzopardi is researching, right here in Malta.

“When I first saw little Matthew struggling to write, I knew we were dealing with something unusual,” Dr. Azzopardi recalls. Matthew, not his real name, is a five-year-old Maltese boy who was diagnosed with a childhood form of ALS. His case, and others like it, have driven Dr. Azzopardi’s quest to understand this rare disease better, hoping to one day find a cure.

Unraveling the genetic code

Dr. Azzopardi’s lab, tucked away in the bustling Msida district, is a hive of activity. Here, she and her team are delving into the genetic code, searching for the mutations that cause this devastating disease. They’re focusing on a gene called C9orf72, which is the most common genetic cause of ALS in adults. Intriguingly, it’s also been found to play a role in some childhood cases.

“We’re looking at how these genetic mutations affect the development and function of neurons,” Dr. Azzopardi explains. “Understanding this could help us develop targeted therapies to slow down, or even stop, the progression of the disease.”

Collaborating across continents

Dr. Azzopardi’s work isn’t just confined to Malta’s shores. She’s part of an international consortium of researchers, collaborating with teams in the UK, Europe, and the US. Together, they’re sharing data, resources, and expertise to tackle this complex condition.

“We’re stronger together,” Dr. Azzopardi says. “By pooling our resources, we can make faster progress. And that’s crucial when we’re dealing with such a devastating disease that affects children.”

One of their key collaborators is Dr. Timothy Miller at the Washington University School of Medicine in St. Louis. He’s been working on ALS for over two decades and is excited about the potential of their collaborative research. “Dr. Azzopardi’s work is a crucial piece of the puzzle,” he says. “Understanding childhood ALS could hold the key to unlocking the mysteries of the adult form too.”

Hope on the horizon

Despite the challenges, there’s hope. Dr. Azzopardi’s team has made significant strides in understanding the molecular mechanisms behind childhood ALS. They’ve identified potential therapeutic targets and are now working on developing drugs to test in preclinical models.

“We’re not there yet,” Dr. Azzopardi admits. “But we’re closer than we’ve ever been. And that gives me hope. It gives me the drive to keep going, to keep fighting for these children and their families.”

Back in her lab, Dr. Azzopardi looks at a photo of Matthew, now seven, his smile wide and bright despite his struggles. “For him, and for all the other children like him, we’ll keep searching, keep fighting, keep hoping.”